Cure through innovation
Breaking news
- 25 June 2019 CRISPR-Cas9 : First in vivo proof-of-concept in Steinert’s myotonic dystrophy, a neuromuscular disease
- 4 June 2019 The first FDA-approved gene therapy for a neuromuscular disease in the United States is a wonderful hope for patients, also a key challenge for France
- 29 May 2019 Gene therapy : Towards a clinical trial for gamma-sarcoglycanopathy, limb-girdle muscular dystrophy
- 25 February 2019 Treatment of X-CGD : positive results of the gene therapy initiated by Genethon
- 24 October 2018 Interview with Frédéric Revah, CEO of Généthon
- 12 October 2018 Co-administration of AAV Vectors with SVP-Rapamycin enables vector re-administration in pre-clinical gene therapy
